New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Circulating Chromogranin A as Surveillance Biomarker in Patients with Carcinoids - The CASPAR Study.
ÌÇÐÄ´«Ã½
Circulating Chromogranin A as Surveillance Biomarker in Patients with Carcinoids - The CASPAR Study. Clinical cancer ÌÇÐÄ´«Ã½ : an official journal of the American Association for Cancer Research Meng, Q. H., Halfdanarson, T. R., Bornhorst, J. A., Jann, H., Shaheen, S., Shi, R. Z., Schwabe, A., Stade, K., Halperin, D. M. 2024Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively indolent but can be more aggressive. The current recommendations for the use of serum CgA for GEP-NET patients are equivocal. This study was designed to validate an automated CgA immunofluorescence assay for monitoring disease progression in GEP-NET patients.A prospective, multi-center blinded observational study was designed to validate an automated chromogranin A (CgA) immunofluorescence assay for monitoring disease progression in GEP-NET patients. Tumor progression was evaluated with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by CT/MRI. An increase = 50% above the prior CgA concentration to a value > 100 ng/mL in the following CgA concentration was considered positive.153 GEP-NET patients were enrolled. Using the pre-specified cut-off of CgA change for tumor progression, specificity was 93·4% (95%-CI: 90·4%-95·5%, p < 0·001), sensitivity 34·4% (25·6%-44·3%), positive predictive value 57·9% (45·0-69·8), negative predictive value (NPV) 84·3% (80·5-87·6), and area under the curve 0·73 (0·67-0·79).Changes in serial measurements of serum CgA had a favorable specificity and NPV, making this test a useful adjunct to routine radiographic monitoring.
View details for
View details for